The biotech capital market is shifting and survival depends on more than innovation. In this exclusive webinar hosted by MSQ Ventures, global leaders share how they are navigating uncertainty, rethinking fundraising, and building partnerships that create real value.
What You Will Learn:
Hear from leaders at Panacea Venture, Decheng Capital, Immutep, and Numab Therapeutics
Learn how companies are adapting to regulatory, market, and geopolitical shifts
Gain practical fundraising strategies from those who closed $60M–$100M+ rounds in 2024
Discover how cross-border deal-making is evolving
Meet the Speakers:
Fay Xing, Partner, Panacea Venture
Global early-stage biotech investor with clinical background and Asia-US focus.
Katherine Xu, Partner, Decheng Capital
Veteran VC managing $2.5B+ in healthcare investments across US and China.
Marc Voigt, CEO, Immutep
CEO of a dual-listed biotech advancing global clinical trials, with recent success in strategic fundraising and pharma collaboration.
Roland Helfenstein, CFO, Numab Therapeutics
CFO of Swiss biotech Numab, leading capital strategy, partnerships, and non-dilutive funding for over a decade.
Can’t attend live? Register anyway, and we’ll send you the session recording after the event. Following the webinar, attendees will also have the chance to schedule a one-on-one session with BiOneCure through MSQ.